Aperio Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $144M | Sell |
3,916,862
-234,213
| -6% | -$8.59M | 0.43% | 40 |
|
|
2020
Q3 | $145M | Sell |
4,151,075
-331,439
| -7% | -$11.6M | 0.49% | 40 |
|
|
2020
Q2 | $139M | Buy |
4,482,514
+296,599
| +7% | +$10.1M | 0.51% | 30 |
|
|
2020
Q1 | $130M | Sell |
4,185,915
-126,667
| -3% | -$4.32M | 0.57% | 25 |
|
|
2019
Q4 | $160M | Sell |
4,312,582
-49,635
| -1% | -$1.77M | 0.58% | 28 |
|
|
2019
Q3 | $149M | Sell |
4,362,217
-933,696
| -18% | -$34M | 0.59% | 27 |
|
|
2019
Q2 | $218M | Sell |
5,295,913
-485,416
| -8% | -$19.3M | 0.89% | 10 |
|
|
2019
Q1 | $233M | Buy |
5,781,329
+30,375
| +0.5% | +$1.22M | 1.01% | 7 |
|
|
2018
Q4 | $238M | Sell |
5,750,954
-26,289
| -0.5% | -$1.09M | 1.2% | 6 |
|
|
2018
Q3 | $242M | Buy |
5,777,243
+136,669
| +2% | +$5.26M | 1.07% | 7 |
|
|
2018
Q2 | $194M | Buy |
5,640,574
+1,229,958
| +28% | +$42M | 0.93% | 9 |
|
|
2018
Q1 | $149M | Buy |
4,410,616
+91,421
| +2% | +$3.14M | 0.74% | 15 |
|
|
2017
Q4 | $148M | Buy |
4,319,195
+693,176
| +19% | +$23.6M | 0.75% | 15 |
|
|
2017
Q3 | $123M | Buy |
3,626,019
+253,035
| +8% | +$8.13M | 0.69% | 16 |
|
|
2017
Q2 | $107M | Buy |
3,372,984
+151,061
| +5% | +$4.76M | 0.66% | 19 |
|
|
2017
Q1 | $105M | Buy |
3,221,923
+111,000
| +4% | +$3.5M | 0.71% | 17 |
|
|
2016
Q4 | $95.9M | Sell |
3,110,923
-415,065
| -12% | -$12.7M | 0.73% | 16 |
|
|
2016
Q3 | $113M | Buy |
3,525,988
+79,296
| +2% | +$2.65M | 0.82% | 9 |
|
|
2016
Q2 | $115M | Buy |
3,446,692
+355,484
| +11% | +$11.3M | 0.9% | 10 |
|
|
2016
Q1 | $86.9M | Buy |
3,091,208
+133,712
| +5% | +$3.82M | 0.74% | 12 |
|
|
2015
Q4 | $90.6M | Buy |
2,957,496
+34,722
| +1% | +$1.09M | 0.83% | 12 |
|
|
2015
Q3 | $87.1M | Buy |
2,922,774
+142,125
| +5% | +$4.56M | 0.89% | 7 |
|
|
2015
Q2 | $88.5M | Buy |
2,780,649
+190,069
| +7% | +$6.19M | 0.91% | 8 |
|
|
2015
Q1 | $85.5M | Buy |
2,590,580
+232,345
| +10% | +$7.39M | 0.96% | 7 |
|
|
2014
Q4 | $69.7M | Buy |
2,358,235
+197,285
| +9% | +$5.66M | 0.86% | 9 |
|
|
2014
Q3 | $60.6M | Buy |
2,160,950
+218,620
| +11% | +$6.14M | 0.82% | 10 |
|
|
2014
Q2 | $54.7M | Sell |
1,942,330
-139,239
| -7% | -$3.97M | 0.79% | 11 |
|
|
2014
Q1 | $63.4M | Buy |
+2,081,569
| New | +$62.1M | 0.89% | 6 |
|
|
2013
Q4 | – | Sell |
-1,700,213
| Closed | -$49.5M | – | 8 |
|
|
2013
Q3 | $46.3M | Buy |
1,700,213
+197,307
| +13% | +$5.37M | 0.89% | 8 |
|
|
2013
Q2 | $39.9M | Buy |
+1,502,906
| New | +$41.5M | 0.95% | 8 |
|
Other funds holding PFE
Aperio Group's PFE Position: Q4 2020 in Review
Aperio Group reduced its Pfizer (PFE) stake by 5.6% in Q4 2020, selling an estimated $8.59M and leaving 3,916,862 shares worth $144M. The position accounts for 0.43% of the portfolio, ranked #40.
Aperio Group first reported a position in PFE in Q2 2013 and has held it in 30 quarters since. The position peaked at $242M in Q3 2018. 2,675 funds tracked by Wall St. Rank hold PFE as of Q4 2020.
- Aperio Group held 3,916,862 shares of Pfizer worth $144M as of Q4 2020.
- Aperio Group sold 234,213 Pfizer shares in Q4 2020, an estimated $8.59M.
- Pfizer made up 0.43% of Aperio Group's portfolio in Q4 2020, its #40 holding.
- Aperio Group first reported a position in Pfizer in Q2 2013 and has held it in 30 quarters since.
- Aperio Group's Pfizer position peaked at $242M in Q3 2018.
- 2,675 funds tracked by Wall St. Rank held Pfizer as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.